Strongbridge Biopharma PLC (NASDAQ:SBBP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “

A number of other equities analysts have also weighed in on SBBP. ValuEngine upgraded shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Oppenheimer Holdings, Inc. started coverage on shares of Strongbridge Biopharma PLC in a research report on Thursday, August 10th. They set an “outperform” rating and a $12.00 price objective for the company. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. Strongbridge Biopharma PLC has an average rating of “Hold” and an average target price of $11.94.

Strongbridge Biopharma PLC (NASDAQ:SBBP) traded down 17.33% on Wednesday, reaching $6.20. 1,236,535 shares of the company were exchanged. Strongbridge Biopharma PLC has a 52 week low of $2.00 and a 52 week high of $8.85. The stock’s market capitalization is $219.08 million. The stock has a 50-day moving average price of $6.88 and a 200 day moving average price of $5.68.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.34) EPS for the quarter, meeting analysts’ consensus estimates of ($0.34). The business had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.84 million. Analysts forecast that Strongbridge Biopharma PLC will post ($2.48) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Strongbridge Biopharma PLC (SBBP) Downgraded by Zacks Investment Research to Sell” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/strongbridge-biopharma-plc-sbbp-downgraded-by-zacks-investment-research-to-sell.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wisconsin Investment Board acquired a new position in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $114,000. Rhumbline Advisers purchased a new position in shares of Strongbridge Biopharma PLC during the 2nd quarter worth approximately $154,000. California State Teachers Retirement System purchased a new position in shares of Strongbridge Biopharma PLC during the 2nd quarter worth approximately $277,000. Teachers Advisors LLC purchased a new position in shares of Strongbridge Biopharma PLC during the 2nd quarter worth approximately $297,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Strongbridge Biopharma PLC during the 2nd quarter worth approximately $331,000. 63.65% of the stock is currently owned by institutional investors.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma PLC (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.